Innate Pharma S.A. Sponsored ADR (IPHA)
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
Innate Pharma Q2 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab.
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
Innate Pharma NASDAQ: IPHA said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs and its preclinical antibody-drug conjugate, or ADC, portfolio.
Innate Pharma Q1 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung cancer.
Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript
Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript
Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript
Innate Pharma S.A. ( IPHA ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Stephanie Cornen - Vice President of Investor Relations, Communication & Commercial Strategy Jonathan Dickinson - CEO & Director Sonia Quaratino - Executive VP & Chief Medical Officer Conference Call Participants Christopher Liu - Lucid Capital Markets, LLC, Research Division Justin Zelin - BTIG, LLC, Research Division Swayampakula Ramakanth - H.C.
Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Innate Pharma (IPHA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript
Innate Pharma S.A. (NASDAQ:IPHA ) Analyst/Investor Day October 28, 2025 8:00 AM EDT Company Participants Jonathan Dickinson - CEO & Director Sonia Quaratino - Executive VP & Chief Medical Officer Stéphanie Cornen Stephanie Cornen - Vice President of Investor Relations, Communication & Commercial Strategy Yannis Morel - Executive VP & COO Conference Call Participants Pierluigi Porcu Chris Stuessy-Vidas Swayampakula Ramakanth - H.C.
Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA ) Q2 2025 Earnings Call September 17, 2025 8:00 AM EDT Company Participants Stéphanie Cornen Jonathan Dickinson - CEO & Director Yannis Morel - Executive VP & COO Sonia Quaratino - Executive VP & Chief Medical Officer Frederic Lombard - Senior VP & CFO Conference Call Participants Bill Ling - Leerink Partners LLC, Research Division Swayampakula Ramakanth - H.C.
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Corporate Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - Chief Executive Officer Yannis Morel - Chief Operating Officer Sonia Quaratino - Chief Medical Officer Frederic Lombard - Chief Financial Officer Conference Call Participants Daina Graybosch - Leerink Partners Swayampakula Ramakanth - H.C.
Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA ) Q4 2024 Earnings Conference Call March 27, 2025 9:00 AM ET Company Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - CEO Yannis Morel - COO Sonia Quaratino - CMO Frederic Lombard - CFO Conference Call Participants Daina Graybosch - Leerink Partners Swayampakula Ramakanth - H.C.
